Chemotherapy-induced nausea and vomiting (CINV) has long been the bane of patients undergoing cytotoxic therapy. This distressing side effect not only diminishes the quality of life for patients but also extends hospital stays, inflating healthcare costs. Despite the best efforts from the medical community, up to 30% of patients still experience breakthrough nausea and vomiting, even when adhering strictly to antiemetic guidelines. The challenge intensifies when dealing with high-risk agents like cisplatin, where, in the absence of antiemetic drugs, over 90% of patients suffer from CINV.
However, the field of pharmacogenetics – the study of how genes affect a person’s response to drugs – is offering a new frontier in the war against CINV. Over the years, the pharmacogenetic landscape of CINV therapy has seen a significant evolution, shifting from dopamine D2 receptor antagonists to 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists.
In the early days, high-dose metoclopramide was the standard go-to for CINV. However, the 1990s introduced a new class of drugs, the ‘setrons,’ with ondansetron leading the charge. These 5-HT3 receptor antagonists proved more effective than their predecessors, but they fell short in managing delayed CINV post-cisplatin administration.
A breakthrough arrived with the development of next-generation 5-HT3 and NK1 receptor antagonists, such as palonosetron and aprepitant. These drugs have revolutionized antiemetic therapy for CINV, updating management guidelines to now recommend a combination of 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids.
But the real game changer lies in the burgeoning field of pharmacogenetics. With advancements in this field, healthcare professionals are now equipped with more targeted and efficient options for treating CINV. The use of specific genetic markers to predict individual responses to different antiemetic drugs can personalize treatment plans and improve patient outcomes. By understanding the genetic influence on CINV, clinicians can tailor therapy to each patient’s unique genetic profile, ensuring more effective and personalized care.
This shift towards precision medicine in the management of chemotherapy-induced side effects underscores the importance of incorporating pharmacogenetic insights into clinical practice for better patient care and treatment outcomes. While the role of pharmacogenetics in mechanisms of CINV has not been fully unraveled, and it is premature to implement results of pharmacogenetic association studies of antiemetic drugs in clinical practice, the future looks promising.
More studies, with uniform genetic profiles and biomarkers relevant for the proposed target and transporter mechanisms, are needed. However, the potential benefits are undeniable. Tackling CINV at the genetic level could redefine how we manage chemotherapy side effects, making the journey a little less painful for those battling cancer. As we continue to innovate, the integration of pharmacogenetics into the standard clinical practice could be the next major leap forward in the world of biotechnology.
Read more from medscape.com
